NEW YORK (GenomeWeb News) – Bruker reported after the close of the market Wednesday that its revenues in the second quarter were up 8 percent year over year, rising to $454.9 million, compared to $420.7 million in Q2 2012.

The results beat the average Wall Street estimate of $426.4 million, as the company saw "weakness in some key markets partially offset by diversified pockets of growth," Bruker President and CEO Frank Laukien said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: issues in reproducibility, circulating DNA predicts breast cancer relapse, and more.

Because of an autoimmune disorder, a man has been shedding live polioviruses for 28 years, according to an analysis appearing in PLOS Pathogens.

Being in a long-term collaboration can increase researchers' citation rates by 17 percent, a recent analysis says.

By analyzing tweets, Canadian researchers examine the public's view of gene patenting.